The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…

Samsung Bioepis

Samsung Bioepis readies assault on EU Herceptin market

Aiming to shield $14B in sales, AbbVie smacks Amgen with a patent suit over Humira biosim